Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N‑[(2S)‑3‑Phenyl‑2‑sulfanylpropanoyl]‑L‑phenylalanyl‑L‑tyrosine is a synthetic tripeptide and experimental small molecule compound. It is structurally related to thiorphan derivatives, featuring a sulfhydryl group and aromatic amino acids. The compound has not been approved for any therapeutic use, nor does it have known clinical indications or trials in humans. Its mechanism of action and pharmacological profile are not well characterized in the public domain, but its structure suggests potential activity as an enzyme inhibitor or peptidase modulator, similar to other retro-thiorphan analogues[1][2][9]. No developer or manufacturer information is available.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-[(2S)-3-Phenyl-2-sulfanylpropanoyl]-L-phenylalanyl-L-tyrosine.